Product Pipeline
EyePoint has developed five FDA-approved products utilizing our proprietary DurasertTM and VerisomeTM Technologies.
We are utilizing our Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions, and are available to collaborate on our VerisomeTM Technology.
| Product/Program | Phase |
|---|---|
| Dexycu (dexamethasone intraocular suspension) 9% | Approved |
| Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg | Approved |
| Yutiq shorter duration treatment | Preclinical |
| Durasert TKI Potential Indication: Wet AMD | Preclinical |
| Collaboration on glaucoma | Preclinical |
| Verisome Technology - PGE Potential Indication: glaucoma | Preclinical |
| Verisome Technology - NSAID Potential Indication: cataract surgery inflammation | Preclinical |
Please complete the form below to receive information on the availability of Dexycu.
DEXYCU Physician Perspective
DEXYCU Patient Perspective
Yutiq® Shorter Duration for Posterior Uveitis
Potential Indication: posterior segment uveitis
EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.
DurasertTM Bioerodible TKI
Potential Indication: Wet AMD
EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs.